NO20062381L - Partikkeldannende sammensetninger inneholdende kondenserte pyrrolokarbazoler - Google Patents

Partikkeldannende sammensetninger inneholdende kondenserte pyrrolokarbazoler

Info

Publication number
NO20062381L
NO20062381L NO20062381A NO20062381A NO20062381L NO 20062381 L NO20062381 L NO 20062381L NO 20062381 A NO20062381 A NO 20062381A NO 20062381 A NO20062381 A NO 20062381A NO 20062381 L NO20062381 L NO 20062381L
Authority
NO
Norway
Prior art keywords
particle
compositions containing
forming
forming compositions
containing condensed
Prior art date
Application number
NO20062381A
Other languages
English (en)
Inventor
Bradley T Mcintyre
Piyush R Patel
Dave Dickason
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20062381L publication Critical patent/NO20062381L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Et ikke-vandig, partikkeldannende, kondensert pyrrolokarbazolinneholdende preparat er beskrevet. I kontakt med et vandig medium, vil det partikkeldannende preparatet spontant dispergere til suspenderte partikler, og derved danne en stabil suspensjon som tilveiebringer sterkt forbedret biotilgjengelighet ved oral administrering av kondenserte pyrrolokarbazol-forbindelser.
NO20062381A 2003-11-20 2006-05-24 Partikkeldannende sammensetninger inneholdende kondenserte pyrrolokarbazoler NO20062381L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/718,077 US7795246B2 (en) 1998-08-06 2003-11-20 Particle-forming compositions containing fused pyrrolocarbazoles
PCT/US2004/037928 WO2005051958A2 (en) 2003-11-20 2004-11-12 Particle-forming compositions containing fused pyrrolocarbazoles

Publications (1)

Publication Number Publication Date
NO20062381L true NO20062381L (no) 2006-06-09

Family

ID=34633209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062381A NO20062381L (no) 2003-11-20 2006-05-24 Partikkeldannende sammensetninger inneholdende kondenserte pyrrolokarbazoler

Country Status (20)

Country Link
US (1) US7795246B2 (no)
EP (1) EP1685137B1 (no)
JP (1) JP2007512333A (no)
KR (1) KR20070006674A (no)
CN (1) CN1882594A (no)
AT (1) ATE520697T1 (no)
AU (1) AU2004292524A1 (no)
BR (1) BRPI0416733A (no)
CA (1) CA2545545A1 (no)
EA (2) EA014713B1 (no)
ES (1) ES2369365T3 (no)
IL (1) IL175374A0 (no)
IS (1) IS8486A (no)
MX (1) MXPA06005714A (no)
NO (1) NO20062381L (no)
NZ (2) NZ547225A (no)
SG (1) SG148175A1 (no)
UA (1) UA87121C2 (no)
WO (1) WO2005051958A2 (no)
ZA (1) ZA200604072B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
EP3801526B1 (en) 2018-05-25 2023-12-27 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
CN112996512B (zh) 2018-08-31 2025-01-03 卡都瑞恩医药公司 用于治疗镰状细胞病的pde9抑制剂
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JP2937446B2 (ja) 1990-09-14 1999-08-23 株式会社資生堂 白髪防止黒化剤
CA2112799A1 (en) 1991-07-03 1993-01-21 Stephen P. Squinto Method and assay system for neurotrophin activity
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
EP0699204B1 (en) * 1993-05-28 1998-04-15 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
JPH08301762A (ja) * 1995-05-12 1996-11-19 Teijin Ltd 肺癌治療剤
JPH08333245A (ja) * 1995-06-07 1996-12-17 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DE69738416T2 (de) 1996-06-18 2008-12-11 Kyowa Hakko Kogyo Co., Ltd. Liposomale zubereitungen von indolocarbazol-derivaten
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE60137069D1 (de) * 2000-10-11 2009-01-29 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen

Also Published As

Publication number Publication date
BRPI0416733A (pt) 2007-01-16
EA010293B1 (ru) 2008-08-29
EA200601004A1 (ru) 2006-10-27
CA2545545A1 (en) 2005-06-09
MXPA06005714A (es) 2006-08-17
NZ577384A (en) 2010-12-24
ZA200604072B (en) 2007-09-26
CN1882594A (zh) 2006-12-20
EA014713B1 (ru) 2011-02-28
EP1685137A2 (en) 2006-08-02
US7795246B2 (en) 2010-09-14
EA200800923A1 (ru) 2008-08-29
HK1089772A1 (en) 2006-12-08
NZ547225A (en) 2009-06-26
IS8486A (is) 2006-05-26
SG148175A1 (en) 2008-12-31
KR20070006674A (ko) 2007-01-11
AU2004292524A1 (en) 2005-06-09
ATE520697T1 (de) 2011-09-15
WO2005051958A3 (en) 2006-01-12
UA87121C2 (ru) 2009-06-25
US20040220176A1 (en) 2004-11-04
WO2005051958A2 (en) 2005-06-09
EP1685137B1 (en) 2011-08-17
IL175374A0 (en) 2006-09-05
JP2007512333A (ja) 2007-05-17
ES2369365T3 (es) 2011-11-29

Similar Documents

Publication Publication Date Title
CY1107855T1 (el) Συνθεσεις που σχηματιζουν σωματιδια οι οποιες περιεχουν τηγμενα πυρρολοκαρβαζολια
ATE387186T1 (de) Neue zusammensetzungen von sildenafil-freier base
DE60204674D1 (de) Retinoid x rezeptormodulatoren
ATE341606T1 (de) Natriumpercarbonatpartikel mit verbesserter lagerstabilit t
CY1113533T1 (el) Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης
MXPA02011319A (es) Analogos antitumorales de ecteinascidina 743.
HRP20030154B1 (en) Preparation of risperidone
NO20021409L (no) Hastighets-kontrollerte partikler
WO2004098516A3 (en) Cyclic derivatives as modulators of chemokine receptor activity
EA200701107A1 (ru) Твердая фармацевтическая композиция, содержащая валсартан
EA200601004A1 (ru) Частицеобразующие композиции, содержащие конденсированные пирролокарбазолы
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
EA200300988A1 (ru) Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина
DE69917278D1 (de) Heterocyclyl sulphonamid derivate
EA200800810A1 (ru) Соль глюкуроновой кислоты и соединения пиперазина
EA200300448A1 (ru) Композиции, включающие соединения модафинила
HRP20050491A2 (en) Surface-modified hard caramels with improved storage life
NO20055882L (no) Farmasoytiske formuleringer omfattende amoksicillin og klavulanat
AR034313A1 (es) Utilizacion de derivados de piridoindolona para la preparacion de medicamentos
DE50313582D1 (de) Fliessfähige, pulverförmige alpha-liponsäure(-derivate) enthaltende zusammensetzung
NO20052392D0 (no) Fremgangsmate for fremstilling av acetylenforbindelser.
ITMI20030175A1 (it) Uso del 2-mercaptoetansolfonato di sodio come agente antivirale
EA200301167A1 (ru) Нафтотиазиновые позитивные аллостерические модуляторы амра-рецепторов
AR048275A1 (es) 4-ciano-n-{(2r)-2[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-n-piridin-2-il-benzamida, formas de dosificacion y composiciones farmaceuticas
DK1337533T3 (da) Resolvering af trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido-1,2a)pyrazin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application